Skip to Content

DBV Technologies S.A.

Company NameDBV Technologies S.A.
Stock SymbolDBVT
Class PeriodFebruary 14, 2018 to August 04, 2020
Lead Plaintiff Motion DeadlineMarch 18, 2019

On December 19, 2018, DBV Technologies revealed that following discussions with the U.S. Food and Drug Administration (FDA), its Biologics License Application (BLA) for Viaskin Peanut in children four to eleven years of age has been voluntarily withdrawn.  The Company stated, "although the agency did not reference any medical or clinical questions with the submission of Viaskin Peanut, the FDA did communicate that the level of detail with regards to data on manufacturing and quality controls was insufficient in the BLA." On this news shares of  DBV Technologies fell $8.39, or nearly 60%, to close at $5.76 on December 20, 2018, thereby injuring investors. 

Submit Your Information

If you suffered a loss on your DBV Technologies S.A. investments or would like to inquire about joining an action to recover your loss under the federal securities laws, please complete the form below. Please note that submission of this form does not by itself form an attorney-client relationship nor does filing out this form mean you have joined any lawsuit.

Shares Purchased

Number of SharesBuy DatePrice Per ShareAdd

Shares Sold

Number of SharesSell DatePrice Per ShareAdd